Publications by authors named "Terry Macintyre"

Claim this Profile
A
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.
Srividya B Balachander, Steven W Criscione, Kate F Byth, Justin Cidado, Ammar Adam, Terry Macintyre

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Jeffrey G Varnes, Thomas Gero, Shan Huang, R Bruce Diebold, Claude Ogoe, Terry MacIntyre

Bioorg Med Chem Lett· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
Edward J Hennessy, Ammar Adam, Brian M Aquila, Lillian M Castriotta, Donald Cook, Terry MacIntyre

J Med Chem· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors.
Tao Wang, Michelle L Lamb, Michael H Block, Audrey Molina Davies, Yongxin Han, Terry MacIntyre

ACS Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of aminopiperidine-based Smac mimetics as IAP antagonists.
Edward J Hennessy, Jamal C Saeh, Li Sha, Terry MacIntyre, Haiyun Wang

Bioorg Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC.
Turker Yilmaz, Tilahun Jiffar, Gabriel de la Garza, Heather Lin, Zvonimir Milas, Terry MacIntyre

Cancer Biol Ther· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Kenneth Thress, Terry Macintyre, Haiyun Wang, Dave Whitston, Zhong-Ying Liu

Mol Cancer Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
Tao Wang, Michelle L Lamb, David A Scott, Haixia Wang, Michael H Block, Terry Macintyre

J Med Chem· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis